Skip to content
Home » Mediplus Pharmaceutical Co., Ltd. Presented the evaluation of the effectiveness of “Ozonated Glycerin (New G lycerin Compound)” combination preparation for atopic dermatitis at the Japanese Dermatological Association

Mediplus Pharmaceutical Co., Ltd. Presented the evaluation of the effectiveness of “Ozonated Glycerin (New G lycerin Compound)” combination preparation for atopic dermatitis at the Japanese Dermatological Association

[Mediplus Pharmaceutical Co., Ltd.] Presented the evaluation of the effectiveness of “Ozonated Glycerin (New Glycerin Compound)” combination preparation for atopic dermatitis at the Japanese Dermatological Association
*Mediplus Pharmaceutical Co., Ltd.*
Press release: July 3, 2024
**
Evaluation of effectiveness of ozonated glycerin (new glycerin compound) combination preparation for atopic dermatitis was presented at the Japanese Dermatological Association.
*Aiming for a formulation that can solve the skin concerns of people suffering from atopic dermatitis as skin care during the remission phase*
123rd Annual Meeting of the Japanese Dermatological Association

Mediplus Pharmaceuticals (Representative Director: Kenji Ito, Headquarters: Shibuya-ku, Tokyo), which has been involved in the application development of ozone for 50 years, will hold a four-day event from June 6th to 9th, 2024 at the Kyoto International Conference Center. The 123rd General Meeting of the Japanese Dermatological Association (The
123rd Annual Meeting of Japanese Dermatology
Association), we presented the safety and efficacy of a formulation containing ozonated glycerin (a new glycerin compound, hereinafter referred to as “OG”), a unique ingredient, for atopic dermatitis. * ■Title name*
Evaluation of safety and efficacy of new glycerin compounds for atopic dermatitis

* ■Performer*
Mediplus Pharmaceutical Co., Ltd.: Gotaro Shioda, Tatsuya Okumura, Risa Tsuruoka

■Japan Dermatological Association and Annual Meeting Overview Director and Executive Fellow Gotaro Shioda gave a poster presentation on the usefulness of OG combination preparations for atopic
dermatitis.

The Japanese Dermatological Association (JDA) was established in 1897 and is an academic organization that aims to advance dermatological research, education, and clinical practice in Japan. We hold academic conferences and specialized seminars every year to share the latest research results and clinical findings. 『The
We contribute to the education of dermatologists and the maintenance of the health of citizens by publishing academic journals such as “Journal of Dermatology” and formulating clinical practice guidelines.
The General Meeting of the Japanese Dermatological Association is Japan’s largest dermatology-related academic conference, held every year. Dermatologists and researchers from all over the country gather here to present and share the latest research results and clinical findings. The general meeting features lectures, poster presentations, and workshops, with the aim of advancing dermatology and improving clinical techniques.
■Background of establishing the safety of OG combination preparations About the multifunctionality of OG

Treatment methods for atopic dermatitis are diversifying, but there is a need for skin care that can be used safely over the long term, not only in the acute phase, but also in suppressing recurrence of inflammation even during the remission phase. Last May, we announced at the annual meeting of the American Society for Investigative Dermatology (SID) that OG has anti-inflammatory effects and
strengthens the skin’s barrier function. AAD) presented the safety and usefulness of OG for atopic dermatitis. This time*
We similarly evaluated the safety and effectiveness of the OG formulation for atopic dermatitis patients* with the aim of
establishing it as a skin care agent during remission.
■Research content and results
* 【the purpose】*
We will evaluate the safety and effectiveness of NGC* aqueous solution and its preparations (aqueous gel** and ointment) with the aim of establishing them as skin care agents during the remission phase of atopic dermatitis patients.

* 【Method】*
・Target: Those with atopic dermatitis in past/current history, those with atopic predisposition such as dryness symptoms
・Location: Inner upper arm, inner forearm
・Duration: 3 weeks
・Measurement: Visual inspection (dermatologist), dermoscopy, stratum corneum moisture content, water transpiration amount
・Sample: Glycerin (comparison), NGC stock solution, and water diluted with NGC stock solution to 1/10, 1/100, and 1/1000
Solution, ointment preparation (NGC±PEG ointment), aqueous gel preparation (NGC±aqueous gel)
*NGC=OG
**Water-soluble gel = Mediplus gel

* [Result] *
Improvements were seen in the following test results, and no irritation or worsening of erythema, edema/papules, scratch marks, or lichenification was observed in all cases.

Safety and efficacy evaluation test results of OG combination preparations for atopic dermatitis
■Future application development of OG combination preparations based on this evaluation

OG has already been recognized for its various effects on the skin, including antibacterial, anti-inflammatory, and barrier regeneration functions*. At AAD, we have also presented on its safety against atopic dermatitis and its effectiveness in improving the water retention capacity of the stratum corneum. *
This time, we were able to confirm that a significant improvement in the moisture content of the stratum corneum was observed with the new OG formulation, and no irritation or worsening of symptoms was observed in the subjects. In the future, we will continue to research and develop formulations that can solve the skin concerns of people suffering from atopic dermatitis as skin care during the remission period. *
*Reference: https://x.gd/U7I6J

■What is Mediplus Pharmaceutical?

Since its founding in 1973, Mediplus Pharmaceutical has been working on the development of ozonation* (Ozonation(R)), an applied technology for utilizing ozone in medical settings. “Ozonated glycerin” is a unique multifunctional ingredient that is both biologically and environmentally friendly and was created during the development process for external skin preparations using this technology. Our company aims to create a society where everyone can live a comfortable life by leveraging our strengths in product-specific development centered on ozonated glycerin.
*Core technology for utilizing ozone that stabilizes ozone, an unstable gas, by reacting it with glycerin.

* 【Company Profile】*
Company name: Mediplus Pharmaceutical Co., Ltd.
Representative: Representative Director Kenji Ito
Head Office: 1-20-4 Sreed EBISU 5F, Ebisu, Shibuya-ku, Tokyo Homepage: https://www.mediplus-pharma.co.jp/
Established: March 1973
Capital: 93,000,000 yen
Business content: Development, manufacturing, and sales of
pharmaceuticals, quasi-drugs, and cosmetics
*About details about this release*
https://prtimes.jp/main/html/rd/p/000000015.000079724.html



Unsubscribe HTML email

Copyright © PR TIMES Corporation All Rights Reserved.